Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa study of K1 injection with temozolomide and radiotherapy in high-grade glioma
CTR20241899Phase 2Terminated
- Sponsor
- Kanghe Biological
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of phytomenadione in glioma, glioblastoma (GBM), Astrocytoma, IDH-mutant, sponsored by Kanghe Biological. Started May 2024; status: terminated.
02
Drugs
phytomenadione
03
Conditions
gliomaglioblastoma (GBM)Astrocytoma, IDH-mutant
Beyond the preview
Go deeper on CTR20241899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241899.